Faropenem

Faropenem should be administered with caution in patients with renal impairment. The dosage should be reduced or the interval between doses should be increased.

It has been reported that in animal studies (rat), the concentration of faropenem in the blood increases. It is due to the obstruction of metabolic fermentation by cilastatin.

It has been reported in animal studies (dog), that the kidney toxicity of faropenem increases.

It has been reported that due to joint usage with carbapenem drugs (meropenem, panipenem and imipenem-cilastatin sodium) the concentration of valproic acid in the blood reduces, and there is a recurrence of epileptic fits.

Faropenem should be administered with caution in patients with poor oral intake or poor general state (since there are cases that show symptoms of vitamin K deficiency, proper monitoring should be done).

Faropenem should be administered with caution in patients with a family history of atopy.

Safety regarding therapy during pregnancy has not been established. In pregnant women or expectant mothers, the medicine should be given only if the benefits of the treatment are greater than the risks involved.

Faropenem is excreted in human milk. Therefore, Faropenem should be given to nursing mothers only if the benefits outweigh the risks.

Faropenem is generally well tolerated. The most frequently reported adverse reactions are diarrhea, abdominal pain, loose bowel movements, nausea and rash.